

BioSpecifics Technologies Corp. Announces Presentations at Three Upcoming Investor Conferences in September

LYNBROOK, NY – September 1, 2011 - BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at three upcoming investor conferences during the month of September 2011.

- **Stifel Nicolaus Weisel Healthcare Conference 2011** (Boston)
Thursday, September 8th, 2011 at 8:00 am EDT
- **Rodman & Renshaw 13th Annual Healthcare Conference** (New York)
Tuesday, September 13th, 2011 at 9:35am EDT
- **UBS Global Life Sciences Conference** (New York)
Tuesday, September 20th, 2011 at 1:00pm EDT

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, five of which include: Dupuytren's contracture; Peyronie's disease; Frozen Shoulder (Adhesive Capsulitis) and human and canine lipoma. Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. More information about the Company may be found on its website at www.biospecifics.com.

Contact:

BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com